4-((tetrahydro-2H-pyran-2-yl)oxy)but-2-ynoic acid | 116053-25-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: 4-((tetrahydro-2H-pyran-2-yl)oxy)but-2-ynoic acid
• 英文别名: 4-[(2-Tetrahydropyranyl)oxy]-2-butynoic Acid；4-(oxan-2-yloxy)but-2-ynoic acid
• CAS: 116053-25-9
• 化学式: C₉H₁₂O₄
• 分子量: 184.192
• InChiKey: UCGWTQLSUYZQJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-((tetrahydro-2H-pyran-2-yl)oxy)but-2-ynoic acid 在 Dowex 50W 作用下， 以 甲醇 为溶剂， 以2.65 g的产率得到4-羟基丁-2-炔酸
  参考文献：
  名称：

  Prodrugs based on masked lactones. Cyclization of .gamma.-hydroxy amides

  摘要：

  DOI：

  10.1021/jo00256a040
• 作为产物：
  描述：

  ethyl 4-((tetrahydro-2H-pyran-2-yl)oxy)but-2-ynoate 在 sodium hydroxide 、 叔丁醇 作用下， 生成 4-((tetrahydro-2H-pyran-2-yl)oxy)but-2-ynoic acid
  参考文献：
  名称：

  [EN] INHIBITORS OF KRAS
  [FR] INHIBITEURS DE KRAS

  摘要：

  Disclosed herein are macrocyclic compounds that inhibit the binding of KRas. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the KRas inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia, lung cancer, colorectal cancer, pancreatic cancer, and other diseases or conditions dependent on KRas interaction.

  公开号：

  WO2023086341A1

文献信息

• Ruthenium-Catalyzed Asymmetric [2 + 2] Cycloadditions between Chiral Acyl Camphorsultam-Substituted Alkynes and Bicyclic Alkenes
  作者：Jordan Goodreid、Karine Villeneuve、Emily Carlson、William Tam

  DOI：10.1021/jo501594g

  日期：2014.11.7

  Ruthenium-catalyzed asymmetric [2 + 2] cycloadditions between chiral acyl camphorsultam-functionalized alkynes and bicyclic alkenes were examined, providing adducts with complete exo stereoselectivity in good overall yield and enantioselectivity (up to 99% and 166:1, respectively), as well as appreciable diastereoselectivity (up to 163:1). The diastereoselectivity showed dependence on the solvent and

  钌催化不对称[2 + 2]之间环加成手性酰基樟脑磺基官能化的炔烃和双环烯烃进行了检查，提供与完整的加合物外良好总产率和对映选择性的立体选择性（高达99％和166：分别1日），以及表现出非对映选择性（高达163：1）。非对映选择性显示出取决于溶剂和温度，以及反应的炔烃和双环烯烃组分的取代模式。通常，对于在醚溶剂中和在较低温度下在N-丙炔基樟脑和双环烯烃之间进行的反应，观察到较高的非对映选择性。
• [EN] ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2<br/>[FR] DÉRIVÉS DE QUINAZOLINE ALCYNE SERVANT D'INHIBITEURS D'ERBB2
  申请人：ENLIVEN THERAPEUTICS INC

  公开号：WO2022006386A1

  公开（公告）日：2022-01-06

  The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.

  本公开涉及一般用于抑制ErbB2的化合物及其组合物，包括ErbB2的突变形式，特别是那些携带Exon 20突变的形式，制备这些化合物和组合物的方法，以及它们在治疗或预防各种癌症中的应用，如肺癌、胶质瘤、皮肤癌、头颈癌、唾液腺癌、乳腺癌、食道癌、肝癌、胃癌、子宫癌、宫颈癌、胆道癌、胰腺癌、结直肠癌、肾癌、膀胱癌或前列腺癌。